Independence Bank of Kentucky Has $4.18 Million Stock Position in Merck & Co., Inc. $MRK

Independence Bank of Kentucky lowered its position in Merck & Co., Inc. (NYSE:MRK) by 10.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,770 shares of the company’s stock after selling 4,076 shares during the quarter. Independence Bank of Kentucky’s holdings in Merck & Co., Inc. were worth $4,182,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. in the third quarter valued at approximately $31,000. Finally, High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Morgan Stanley increased their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Bank of America boosted their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $132.72.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK traded down $1.35 during trading hours on Friday, hitting $123.72. 8,388,403 shares of the stock were exchanged, compared to its average volume of 10,797,806. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company’s 50 day moving average is $118.83 and its 200 day moving average is $116.28. The firm has a market capitalization of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.68 and a beta of 0.19. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $130.29.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.